Topics:
Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University • NCI-CCC Thoracic Tumor Board Question
For a patient with metastatic NSCLC who had progression x2 at a single site treated w RT, would you switch systemic treatment?
Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation.
Answer from: Medical Oncologist at Community Practice
Continue immunotherapy.
Sign in or Register to read more